Skip to main content
Log in

Regulatory Environment and Approvals in Cell and Gene Therapy Products Between Japan, the USA, and the EU

  • Original Research
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Background

This study aimed to demonstrate the differences in the way cell and gene therapy (CGT) products have been developed and reviewed for approval in Japan, the USA, and the EU by comparing regulations and successfully launched products in each region, and to examine the background to such differences.

Methods

Information on relevant regulations and approved CGT products were collected from the public source and compared by region.

Results

While regulations on CGT products are largely consistent among these regions, some differences could have a substantial impact on the practices defining CGT products, the timing of responses required to comply with the regulations for handling gene-modified organisms, and the acceptable validation processes under good manufacturing practice regulations. Although CGT products are given some preferential status in all regions, the preferential treatment given to CGT products varies across regions. The CGT products launched in each region also differ significantly in type, indications, the nature of the developers, and the clinical evidence submitted. While all the cellular products launched in Japan were approved based on small uncontrolled trials, most cellular products in the USA and EU were approved based on controlled studies. A trend was observed for companies to enter their home markets.

Conclusion

Our study showed differences of regulations on CGT products and of features in approved products as well as the trend of their home market entries, which may have been driven by a different context than that of traditional pharmaceuticals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Smith DM, Culme-Seymour EJ, Mason C. Evolving industry partnerships and investments in cell and gene therapies. Cell Stem Cell. 2018;22(5):623–6.

    Article  CAS  Google Scholar 

  2. Moody J, Milligan WD, St Onge M, et al. Cell and gene therapy: a snapshot of investor perspectives. Cytotherapy. 2021;23(3):256–60.

    Article  Google Scholar 

  3. Atilla E, Kilic P, Gurman G. Cellular therapies: day by day, all the way. Transfus Apher Sci. 2018;57(2):187–96.

    Article  Google Scholar 

  4. Coppens DGM, de Wilde S, Guchelaar HJ, et al. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: an evaluation of regulatory decision-making. Cytotherapy. 2018;20(6):769–78.

    Article  CAS  Google Scholar 

  5. Ramezankhani R, Torabi S, Minaei N, et al. Two decades of global progress in authorized advanced therapy medicinal products: an emerging revolution in therapeutic strategies. Front Cell Dev Biol. 2020;8:547653.

    Article  Google Scholar 

  6. Coppens DGM, De Bruin ML, Leufkens HGM, et al. Global regulatory differences for gene- and cell-based therapies: consequences and implications for patient access and therapeutic innovation. Clin Pharmacol Ther. 2018;103(1):120–7.

    Article  CAS  Google Scholar 

  7. Kusakabe T. Regulatory perspectives of Japan. Biologicals. 2015;43(5):422–4.

    Article  Google Scholar 

  8. Fujiwara Y, Maruyama Y, Honda F. Balancing safety and efficacy with early availability in the regulation of regenerative medicine product. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.2034.

    Article  Google Scholar 

  9. Gee AP. Regulation of regenerative medicine products. Adv Exp Med Biol. 2018;1098:189–98.

    Article  CAS  Google Scholar 

  10. Bachtarzi H, Farries T. The genetically modified organism medicinal framework in Europe, United States, and Japan: underlying scientific principles and considerations toward the development of gene therapy and genetically modified cell-based products. Hum Gene Ther Clin Dev. 2019;30(3):114–28.

    Article  CAS  Google Scholar 

  11. Cox EM, Edmund AV, Kratz E, et al. Regulatory affairs 101: introduction to expedited regulatory pathways. Clin Transl Sci. 2020;13(3):451–61.

    Article  Google Scholar 

  12. Tanaka M, Idei M, Sakaguchi H, et al. Achievements and challenges of the Sakigake designation system in Japan. Br J Clin Pharmacol. 2021. https://doi.org/10.1111/bcp.14807.

    Article  Google Scholar 

  13. Public Health Service Act, Section 351. 42 U.S.C. §262.

  14. Federal Food, Drug, and Cosmetic Act. 21 U.S.C. § 321–399i.

  15. Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products (OJ L 242, 15.9.2009, p. 3–12).

  16. The Act on Securing Quality, Efficacy, and Safety of Products, including Pharmaceuticals and Medical Devices. Act No. 145 of August 10, 1960, and its amendments.

  17. FDA Guidance for Industry, Expedited Programs for Regenerative Medicine Therapies for Serious Conditions. 2019.

  18. Trial Implementation of SAKIGAKE review designation. Notification No. 0401 (dated on 1 April 2015) issued by the Director of Evaluation and Licensing Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW.

  19. Handling of the Designation for Pioneering Medical devices, IVDs, Regenerative Medical Products, etc. Notification No. 6 (dated on 31 August 2020) issued by the Director of Medical Device Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW.

  20. FDA Guidance For Industry, Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products. 2015.

  21. Act on the Conservation and Sustainable Use of Biological Diversity through Regulations on the Use of Living Modified Organisms. Act No. 97 of June 18, 2003, and its amendments.

  22. Partial revision of "Revised procedures under Act on the Conservation and Sustainable Use of Biological Diversity through Regulations on the Use of Living Modified Organisms". Notification No. 5 (dated on 30 September 2021) issued by the Director-general of Pharmaceutical Safety and Environmental Health Bureau, MHLW. (To supplement “Questions and answers on administrative procedures, etc. for application for approval based on the law concerning the conservation of biodiversity through regulations on use of living modified organisms, etc. Administrative Notification issued by Pharmaceutical Evaluation Division and Medical Device Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated on 3 February 2022.” is also referred.)

  23. Concept of residual non-proliferative recombinant viruses used in the production of gene transduced cells. Administrative Notification issued by Evaluation and Licensing Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated on 10 December 2020.

  24. Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Regenerative Medical Products. Ordinance of Ministry of Health, Labour and Welfare, No. 93, August 6, 2014.

  25. Good Manufacturing Practice for Advanced Therapy Medicinal Products. EudraLex Volume 4 Part IV. 2017.

  26. Kyle MK. The role of firm characteristics in pharmaceutical product launches. Rand J Econ. 2006;37(3):602–18.

    Article  Google Scholar 

  27. Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs—evidence from twenty-five major markets in the 1990s. Health Econ. 2005;14(3):269–92.

    Article  Google Scholar 

  28. Dranove D, Meltzer D. Do important drugs reach the market sooner. Rand J Econ. 1994;25(3):402–23.

    Article  Google Scholar 

  29. Kyle MK. Pharmaceutical price controls and entry strategies. Rev Econ Stat. 2007;89(1):88–99.

    Article  Google Scholar 

  30. FDA. What is Gene Therapy? https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy. Accessed 25 July 2018.

  31. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004.

  32. Directive 2001/18/EC on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC.

  33. Salmikangas P, Menezes-Ferreira M, Reischl I, et al. Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use. Regen Med. 2015;10(1):65–78.

    Article  CAS  Google Scholar 

  34. Handling of Priority Review. Notification No. 1 (dated on 31 August 2020) issued by the Directors of Pharmaceutical Evaluation Division and of Medical Device Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW.

  35. FDA Guidance For Industry, Expedited Programs for Serious Conditions – Drugs and Biologics. 2014.

  36. PMDA. Timeline for Standard Process of New Drug Review. https://www.pmda.go.jp/review-services/drug-reviews/about-reviews/p-drugs/0014.html. Accessed 14 Nov 2021.

  37. MHLW. SAKIGAKE Package Strategy – Promotion of Commercializing Innovative Medicines 2014. https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/topics/tp140729-01.html. Accessed 26 Jan 2021

Download references

Funding

This study was funded by a Japanese government-based grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan (KAKEN-HI: 19K07215).

Author information

Authors and Affiliations

Authors

Contributions

YS and SO wrote the manuscript; YS and SO designed the research; YS analyzed the data.

Corresponding author

Correspondence to Shunsuke Ono PhD.

Ethics declarations

Conflict of interest

YS is an employee of Novartis Pharma K.K. The other author declared no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sato, Y., Ono, S. Regulatory Environment and Approvals in Cell and Gene Therapy Products Between Japan, the USA, and the EU. Ther Innov Regul Sci 57, 227–237 (2023). https://doi.org/10.1007/s43441-022-00455-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43441-022-00455-4

Keywords

Navigation